Pharmaceutical / Drug Definition :
Selectively binds to GH receptors on cell surfaces, where it blocks binding of endogenous GH and interferes with GH signal transduction. This action decreases blood levels of insulin-like growth factor-1 (IGF-1) and other GH-responsive serum proteins.
In the United States, Pegvisomant is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Pegvisomant.
Pegvisomant (Pegvisomant Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Pegvisomant (Pegvisomant Suppliers)
- Processors Pegvisomant
- Repackers Pegvisomant
- Relabelers Pegvisomant
- Exporters Pegvisomant
- Importers Pegvisomant
For more information about Pegvisomant, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.